Post #13 by LucidDreamer on the Esperion Therapeutics board

Shrewd'm.com

A merry & shrewd investing community

Best Of ESPR | Best Of | Favourites & Replies | All Boards | Post of the Week!

Search ESPR

Shrewd'm.com Merry shrewd investors
Best Of ESPR | Best Of | Favourites & Replies | All Boards | Post of the Week!

Search ESPR

We take risks and make bets
On what the future holds
But always with a Shrewd eye
And a well-calculated goal

- Manlobbi

Stocks A to Z / Stocks E / Esperion Therapeutics (ESPR)

Unthreaded | Threaded | Whole Thread (1)

Prev | Next

Post New | Post Reply | Report Post | Recommend It!

No. of Recommendations: 3

Otsuka, the Japan partner, took the expected next step of submitting the drug so they can start selling in 2025. This is expected to trigger a $20m milestone payment to Esperion, presumably here in Q4.

While expected, it is good to see things moving forward.

https://www.esperion.com/news-releases/news-releas...

Dreamer

Post New | Post Reply | Report Post | Recommend It!

Print the post

Unthreaded | Threaded | Whole Thread (1)

Prev | Next

Announcements

Esperion Therapeutics FAQ

Contact Shrewd'm
Contact the developer of these message boards.

Ticker or Board Name Author

A community forum supporting civilized, and highly helpful, self-educating investors that come together for Shrewdness and merry spirits. These message boards closely follow the look and feel of the old message boards at boards.fool.com prior to the boards redirected to discussion.fool.com. Shrewd'm is not affiliated with the comprehensive and excellent investment website, The Motley Fool (TMF), in any way. The Shrewd commmunity here has owed, and continues to owe, gratitude to The Motley Fool for nurturing a culture of jovial irreverence towards Wall St, and that tradition will continue here.